Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia): An article from: Internal Medicine News
This digital document is an article from Internal Medicine News, published by International Medical News Group on July 15, 2002. The length of the article is 497 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia)
Author: Sharon Worcester
Publication: Internal Medicine News (Magazine/Journal)
Date: July 15, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 14 Page: 25(1)
Article Type: Prod
List Price: $ 5.95
Price: $ 5.95
Leukemia — Comprehensive overview covers symptoms, causes, risk factors, treatment of this blood-related cancer.
Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia): An article from: Internal Medicine News
New! 11 Chronic Pain eBooks - Earn 70
80% of people suffer chronic back pain. High converting ebooks - back pain, neck pain, bursitis pain, buttock pain, shoulder pain, hip pain, sciatica, tendonitis, natural healing. Get hoplinks here: www.free-from-chronic-pain.com/affiliates.htm
New! 11 Chronic Pain eBooks - Earn 70
Related Chronic Myeloid Leukemia Phase Products
Orignal From: Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia): An article from: Internal Medicine News Reviews
No comments:
Post a Comment